Register for our free email digests:
Division of TiGenix NV
Latest From Food & Drug Administration
Which immuno-oncology candidates are poised to begin their first-in-human clinical trials? How many sponsors already have partners or collaborators? What oncology indications have been proposed? And where will these trials take place? Citeline's Rachel L. Meighan-Mantha has the data.
Mobile technology and wearables have been hailed by many as the golden future for operational efficiency and patient retention in clinical studies. Digital engagement expert Tim Davis discusses the pitfalls of selecting a one-size-fits-all strategy and waiting for trial processes and regulators to catch up.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- TiGenix NV
- Senior Management
Andrew K Lynn, CEO
Max D Bartlett, Dir., Fin.
Mark Withers, Head, Sales & Mktg.
- Contact Info
Phone: (44) 1223 437470
Cambridge Bus. Park, Milton Rd.
Cambridge, CB4 0WZ
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.